Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report ; volume:6 ; number:1 ; day:23 ; month:4 ; year:2012 ; pages:1-5 ; date:12.2012
Journal of medical case reports ; 6, Heft 1 (23.4.2012), 1-5, 12.2012
- Creator
-
Michalaki, Vasiliki
- Contributor
-
Gennatas, Constantine
SpringerLink (Online service)
- DOI
-
10.1186/1752-1947-6-115
- URN
-
urn:nbn:de:1111-2016071027758
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Michalaki, Vasiliki
- Gennatas, Constantine
- SpringerLink (Online service)
Other Objects (12)
Targeted therapy of DC-CIK cells in renal cell carcinoma
Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy
How I prescribe prolonged intermittent renal replacement therapy
Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy
Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma
Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma
Systemic therapy of renal cell carcinoma
Life-threatening gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: a case report
Systemic therapy in metastatic renal cell carcinoma
Tubule-specific protein nanocages potentiate targeted renal fibrosis therapy
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations
Is prolonged intermittent renal replacement therapy actually safe for hemodynamically unstable patients
Targeted therapy of DC-CIK cells in renal cell carcinoma
Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy
How I prescribe prolonged intermittent renal replacement therapy
Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy
Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma
Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma
Systemic therapy of renal cell carcinoma
Life-threatening gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: a case report
Systemic therapy in metastatic renal cell carcinoma
Tubule-specific protein nanocages potentiate targeted renal fibrosis therapy
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations
Is prolonged intermittent renal replacement therapy actually safe for hemodynamically unstable patients
Targeted therapy of DC-CIK cells in renal cell carcinoma
Molecular subtyping of metastatic renal cell carcinoma: implications for targeted therapy
How I prescribe prolonged intermittent renal replacement therapy
Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy
Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma
Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma
Systemic therapy of renal cell carcinoma
Life-threatening gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: a case report
Systemic therapy in metastatic renal cell carcinoma
Tubule-specific protein nanocages potentiate targeted renal fibrosis therapy
Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations